Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

Randomized Pilot Study of Supplemental Iscar in Combination With Gemcitabine vs. Gemcitabine Alone as Second Line Treatment for Advanced Non-Small Cell Lung Cancer.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00283478

Enrollment

Registered

2006-01-30

Start date

2004-05-31

Completion date

2007-04-30

Last updated

2007-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Keywords

Advanced stage, Lung cancer

Brief summary

To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.

Detailed description

RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine alone as second line treatment for advanced non-small cell lung cancer.

Interventions

DRUGIscar Quercus

DRUGGemcitabine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo * Karnofsky score 60% or greater * patients who will be treated with Gemcitabine

Design outcomes

Primary

Measure	Time frame
To determine if Iscar improves immune function and quality of life.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026